Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain.
Department of Pharmacy, Hospital Universitario Miguel Servet, Zaragoza, Spain.
J Comp Eff Res. 2021 Mar;10(4):325-335. doi: 10.2217/cer-2020-0233. Epub 2021 Feb 26.
To assess the cost-effectiveness of first-line treatment with dacomitinib compared with gefitinib in patients newly diagnosed with advanced NSCLC -positive in the context of Spain. A partitioned survival model was developed including costs, utilities and disutilities to estimate quality-adjusted life-year (QALY) and incremental cost-effectiveness ratio when treating with dacomitinib versus gefitinib. Dacomitinib presented higher QALYs (0.51) compared with gefitinib (0.45). Dacomitinib costs were €33,061 in comparison with €26,692 for gefitinib arm. An incremental cost-effectiveness ratio of €111,048 was obtained for dacomitinib. Dacomitinib was more effective in terms of QALYs gained than gefitinib. However, to obtain a cost-effectiveness alternative, a discount greater than 25% in dacomitinib acquisition cost is required.
评估达可替尼与吉非替尼作为一线治疗药物在西班牙新诊断的晚期 NSCLC 阳性患者中的成本效益。建立了一个分割生存模型，包括成本、效用和非效用，以估计使用达可替尼与吉非替尼治疗时的质量调整生命年（QALY）和增量成本效益比。与吉非替尼（0.45）相比，达可替尼（0.51）具有更高的 QALY。达可替尼的成本为 33061 欧元，而吉非替尼组的成本为 26692 欧元。达可替尼的增量成本效益比为 111048 欧元。与吉非替尼相比，达可替尼在获得 QALY 方面更有效。然而，要获得成本效益的替代方案，需要达可替尼购买成本降低 25%以上。
